QualityDipStocks / Health Care · Biotech
Replimune Group REPL
Outside our quality screen, so we don’t track its dips. It’s at its 52-week high.
Outside our quality screen. No fair value estimate for now: its free cash flow is negative.
Worth knowing
- Net cash = 12% of its market cap
From the data on this page, as of the last close. How we pick these
- Fair value est.
- n/a
- Market Value
- forming
- Off 52-wk high
- at the high
- Risk vs market
- Market-likebeta 0.98
52-week range at its 52-week high
Price $19.49
2 bullish · 5 bearish See why
Valuation
What we estimate it's worth, and how it ranks on value vs every stock we cover.
Fair value estimate
No estimate for REPL: negative free cash flow. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 31 to Nov 2, 252 sessions). Beta = how much REPL moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Moves about in line with the market, and its own price swings are 14.7× the S&P 500’s.
- Beta vs S&P 500
- 0.98
- Volatility
- 188% vs 13% SPY
- Correlation SPY
- 0.07
- Correlation QQQ
- 0.08
Valuation details
Fundamentals
The business itself: sales, profits, cash and debt, from SEC filings.
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 2 of 5
Balance sheetNet cash of $208M: cash and short-term investments exceed debt (Sep 30, 2026).
Balance sheetDebt / equity of 0.5×, below the 0.5× median for the 161 Health Care companies we cover.
Top bearish points 5 of 5
ValuationFree cash flow is negative (−$246M over the last 12 months), so there’s no cash-flow value under the price.
Balance sheetOperating income covers interest only -30.2× over the last 12 months.
ProfitabilityLost $271M over the last 12 months (net income, SEC filings).
ProfitabilityReturn on equity fell 131 points in two fiscal years, to -189% in FY2026.
QualityDoesn’t pass our quality screen: no positive free cash flow; ROE under 12% and ROIC under 10%; no sales-growth data.
All fundamentals
FCF yield -13.7% · ROE -116%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/anegative free cash flow
- FCF yield
- −13.7%
- EV / EBITDA
- n/anegative EBITDA
- Price / sales
- n/anot reported in its SEC filings
- Price / book
- 8.79×
- Market cap
- $1.8Blisted
- Enterprise value
- $1.6B
Growth
- Revenue, 12 months
- n/anot reported in its SEC filings
- Sales growth, 12 months
- n/ano year-ago 12-month revenue
- Sales growth, 3 yrs
- n/anot reported in its SEC filings
- Diluted EPS, 12 months
- −$2.79
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$271M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- n/anot reported in its SEC filings
- Net margin
- n/anot reported in its SEC filings
- FCF margin
- n/anot reported in its SEC filings
- Return on equity
- −116%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $308M
- Total debt
- $100M
- Net cash
- $208M
- Debt / equity
- 0.49×
- Interest coverage
- -30.2×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- −$246M
- FCF growth, 12 months
- n/anot reported in its SEC filings
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +14.4%diluted shares vs a year ago
- Stock-based comp
- $33M
Trailing 12 months to Sep 30, 2026; balance sheet at Sep 30, 2026. From Replimune Group’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
The business
FCF $-0.2B
- Free cash flow, 12 months−$0.2B
- Free-cash-flow yield-13.7%
- Gross margin0%
- Operating margin0%
- Return on equity−116%
Chart & levels
Where the price is vs its key levels and trends.
Key levels
Every level vs today’s $19.49
- 52-wk lowlowest close, 1 year$1.70−91.3%
- 52-wk highhighest close, 1 year$19.49at the price
- PriceMon Nov 2 close$19.49you are here
Momentum & 52-week range
RSI 80 · 5 days +56.3%
Signals
Reversal signal setups, the public ledger and the next earnings date.
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
REPL is outside our quality screen
One text when a published rule fires on one of the 332 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.
Voices & buzz
Who is talking about it, and how it compares with peers.
Who’s talking about it
Notable investors, executives, analysts and public figures on Replimune Group in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 3, 5:14 PM ET.
Compare with peers
Closest in size in Biotech
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.